Affinity Asset Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Affinity Asset Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.92M	Buy	+1,750,000	New	+$2.27M	0.12%	101

Other funds holding PMVP

BCM

BML Capital Management Zionsville, Indiana $188M AUM 88.51% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

BIT Capital Berlin, Germany $2.89B AUM 111.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Aldebaran Capital Carmel, Indiana $139M AUM 35.88% 1-Year Est. Return

Walleye Capital New York $109B AUM 29.28% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Affinity Asset Advisors's PMVP Position: Q3 2026 in Review

Affinity Asset Advisors opened a new position in PMV Pharmaceuticals (PMVP) in Q3 2026: 1,750,000 shares worth $2.92M. The stake represents 0.12% of the portfolio and ranks #101 among its holdings.

36 funds tracked by Wall St. Rank hold PMVP as of Q3 2026.

Affinity Asset Advisors held 1,750,000 shares of PMV Pharmaceuticals worth $2.92M as of Q3 2026.
PMV Pharmaceuticals was a new Affinity Asset Advisors position in Q3 2026.
PMV Pharmaceuticals made up 0.12% of Affinity Asset Advisors's portfolio in Q3 2026, its #101 holding.
36 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2026.

Based on Affinity Asset Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.